TABLE 2.
VLDL-TG kinetics in subjects treated with anacetrapib in combination with atorvastatin (panel A) or anacetrapib alone (panel B)
| Panel A (N = 28) | Panel B (N = 10) | All Subjects (N = 38) | ||||||||||
| Period 1 (ATV) | Period 2 (ANA+ATV) | Percent Change from Period 1 (95% CI) | P | Period 1 (PBO) | Period 2 (ANA) | Percent Change from Period 1 (95% CI) | P | Period 1 | Period 2 | Percent Change from Period 1 (95% CI) | P | |
| VLDL-TG PS (mg) | 3,778 (56.5) | 3,235 (58.9) | −14.4 (−23.1, −4.6) | 0.006 | 3,740 (78.9) | 3,696 (64.6) | −1.2 (−17.5, 18.3) | 0.894 | 3,759 (61) | 3,458 (60) | −8.0 (−17.2, 2.2) | 0.115 |
| VLDL-TG FCRa (pools/day) | 7.32 (3.3) | 10.45 (6.04) | 29.4 (5.9, 52.8) | 0.002 | 5.64 (3.4) | 7.77 (2.2) | 40.7 (−15.0, 64.4) | 0.105 | 6.78 (3.75) | 8.54 (5.9) | 31.4 (10.8, 52.6) | <0.001 |
| VLDL-TG PR (mg/kg/day) | 324.6 (57.0) | 370.2 (54.9) | 14.1 (−2.1, 32.8) | 0.089 | 306.5 (53.0) | 425.1 (72.7) | 38.7 (7.4, 79.0) | 0.014 | 315.4 (55.2) | 396.7 (59.1) | 25.8 (8.4, 45.9) | 0.004 |
| VLDL-TG PR/VLDL apoB PR (mg/mg) | 21.5 (19.0) | 23.4 (14.9) | 18.1 (0.1, 38.5) | 0.048 | 19.6 (20.5) | 15.0 (39.4) | −2.5 (−31.5, 40.5) | 0.846 | 20.4 (18.7) | 23.1 (23.9) | 11.3 (−3.0, 28.1) | 0.136 |
Mixed model analysis performed on log scale. Geometric mean (% CV) displayed under period 1 and period 2. Percent change from period 1 and corresponding 95% CI calculated using 100 × (GMR − 1). ATV, atorvastatin; ANA, anacetrapib; PBO, placebo.
a
Nonparametric method used. Median (IQR) on raw scale displayed under period 1 and period 2. Hodges-Lehmann estimate (95% CI) back transformed from log scale displayed under percent change from period 1. P value from Wilcoxon signed rank test.